GI Signals - Esophagus/Refluxhttps://siftingsignal.com/gisignals/Esophagus/Reflux papers worth knowing in GI this week. A SiftingSignal publication.Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42437376https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42437376Sat, 18 Jul 2026 20:04:34 +0000Alimentary pharmacology & therapeutics. Screen hEDS/HSD patients for chronic GI symptoms (especially heartburn, dysphagia, GERD) following SOC for GERD (alarm feature assessment first, empiric PPI trial if no alarms). Assess for comorbid DGBIs (functional dysphagia 34.2%) and extraintestinal conditions (chronic fatigue 49%, migraine 38.2%, OI 35.9%, POTS 21.9%).Comparison of Fully Covered Self-Expanding Metal Stents and Liquid Nitrogen Spray Cryotherapy for Malignant Esophageal Adenocarcinoma: A Retrospective Cohort Study.https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42456982https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42456982Sat, 18 Jul 2026 20:04:34 +0000Gastrointestinal endoscopy. In the palliative setting for malignant esophageal obstruction, consider liquid nitrogen spray cryotherapy with balloon dilation (LNSC) as an alternative to fully covered self-expanding metal stents (FCSEMS), particularly for patients at higher risk of stent-related complications (migration, intolerance). LNSC showed fewer adverse events and a trend toward better dysphagia improvement, though clinical success did not reach statistical significance.Eosinophilic Esophagitis and Autoimmune Thyroid Disease: A Population-Based Matched Cohort Study.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42383463https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42383463Thu, 09 Jul 2026 16:47:07 +0000United European gastroenterology journal. Consider heightened awareness for AITD symptoms in childhood-onset EoE patients (HR 2.53 for future AITD, OR 4.71 for prior AITD). No routine screening recommended for adult-onset EoE (HR 1.18, 95% CI 0.91-1.54).Incidence of Gastrointestinal Adverse Events and Healthcare Resource Utilization in Patients Using Glucagon-Like Peptide-1 Analogs: A Real-World Study.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42418075https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42418075Thu, 09 Jul 2026 16:47:07 +0000Digestive diseases and sciences. Counsel patients with DM or obesity starting GLP-1 analogs about the high likelihood (1 in 3) of GI side effects, particularly nausea, vomiting, and GERD, and monitor for gastroparesis symptoms (early satiety, bloating). Note the reduced bowel obstruction risk and no significant increase in ER visits or hospitalizations despite higher EGD use.